Areas of the report will require further detailed examination in order to ensure that a new pricing and reimbursement system benefits both patients and the economy by recognising the value that the research-based pharmaceutical industry brings in developing new and innovative medicines. The ABPI would like to see a proper understanding of the nature of pharmaceutical innovation – specifically the terms breakthrough and incremental need significantly more clarity.
The existing PPRS system includes provision to stimulate the growth of the pharmaceutical industry as part of the health of the economy but it is as yet unclear if this will be included in VBP. We have serious concerns that the plans to encourage and nurture life sciences via the Plan for Growth in isolation will not deliver the joined-up industrial policy that we believe is essential.
Our preference is for one unitary pricing and reimbursement system that includes the commitment to value based pricing, minimises bureaucracy and ensures rapid access for patients to new medicines. We have still to see a clear vision of the system that will succeed the current PPRS, which has traditionally met patient needs and supported an important research and development based industry.
ABPI CEO Stephen Whitehead said:
"There is much work to be done on the new pricing and reimbursement system and many questions to be answered. The goal is to achieve a scheme under which patients have the best possible health outcomes. This will be achieved by a system that both ensures access to new and innovative medicines and creates the best environment for the research-based pharmaceutical industry in the UK to develop them. The ABPI is confident that we can establish a productive working framework to take us through to the next steps and welcomes the open approach of the Department of Health in progressing this."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
About the ABPI
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.